MiR-27b-5p promotes gastric cancer progression by targeting CREBZF to regulate the STAT3 pathway

Table 1 Sequences of primers used in this study

Primers	Sequences (5’-3’)
H-miR-27b-5p	AGCTTAGCTGATTGGTGAAC
H-cyclin D1-F	GAGGAACAGAAGTGCGAGGAG
H-cyclin D1-R	TGGAGTTGTCGGTGAGATGC
H-c-myc-F	GGGTAGTGGAAAACCAGCCT
H-c-myc-R	AGAAATACGGCTGCACCGAG
H-Bax-F	CAGACCGTGACCATCTTTGTG
H-Bax-R	CTCAGCCCATCTTCTTCCAG
H-Bcl-2-F	TGGCCTTCTTTGAGTTCGG
H-Bcl-2-R	TCCACAGGGCGATGTTGTC
H-survivin-F	TGAGAACGAGCCAGACTTGG
H-survivin-R	TTCCTTTGCATGGGGTCGTC
H-CREBZF-F	GGGAAAGCAGAAGCAGGAC
H-CREBZF-R	GAGCAGAACTCCACCGACAC
H-ACTB-F	AGTCATTCCAAATATGAGATGCGTT
H-ACTB-R	TGCTATCACCTCCCCTGTGT
H-U6-F	CTCGCTTCGGCAGCACA
H-U6-R	AAAATATGGAACGCTTCACG

CREBZF: cAMP response element-binding protein zinc finger; Bcl-2: B-cell lymphoma 2; Bax: Bcl-2-associated X protein.

Table 2 Association between plasma miR-27b-5p levels and clinicopathological features in 168 gastric cancer patients

Characteristics	n	MiR-27b-5p expression	Mann-Whitney U	P value
Gender
Male	108	0.1183	3071	0.5763
Female	60	0.1162
Age
≥ 60	48	0.1134	2603	0.3315
< 60	120	0.1177
T
T1	71	0.0934	1871	P < 0.0001
T2 + T3 + T4	97	0.2031
N
N0	113	0.1088	2347	0.0098
N1 + N2 + N3	55	0.1984
M
M0	137	0.1132	1569	0.0228
M1	31	0.2404
Clinical stages
I	107	0.1063	2208	0.0004
II + III + IV	61	0.2243